Last Updated: November 16, 2026

ACORAMIDIS HYDROCHLORIDE - Generic Drug Details

« Back to Dashboard


What are the generic sources for acoramidis hydrochloride and what is the scope of patent protection?

Acoramidis hydrochloride is the generic ingredient in one branded drug marketed by Bridgebio Pharma and is included in one NDA. There are thirteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for ACORAMIDIS HYDROCHLORIDE
International Patents:123
US Patents:13
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 9
Patent Applications: 20
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for ACORAMIDIS HYDROCHLORIDE
What excipients (inactive ingredients) are in ACORAMIDIS HYDROCHLORIDE?ACORAMIDIS HYDROCHLORIDE excipients list
DailyMed Link:ACORAMIDIS HYDROCHLORIDE at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ACORAMIDIS HYDROCHLORIDE
Generic Entry Date for ACORAMIDIS HYDROCHLORIDE*:
Constraining patent/regulatory exclusivity:
Dosage:

TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ACORAMIDIS HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
BayerPHASE4
Eidos Therapeutics, a BridgeBio companyPHASE3
CelerionPhase 1

See all ACORAMIDIS HYDROCHLORIDE clinical trials

Pharmacology for ACORAMIDIS HYDROCHLORIDE
Anatomical Therapeutic Chemical (ATC) Classes for ACORAMIDIS HYDROCHLORIDE

US Patents and Regulatory Information for ACORAMIDIS HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bridgebio Pharma ATTRUBY acoramidis hydrochloride TABLET;ORAL 216540-001 Nov 22, 2024 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Bridgebio Pharma ATTRUBY acoramidis hydrochloride TABLET;ORAL 216540-001 Nov 22, 2024 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Bridgebio Pharma ATTRUBY acoramidis hydrochloride TABLET;ORAL 216540-001 Nov 22, 2024 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for ACORAMIDIS HYDROCHLORIDE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2934514 C202530015 Spain ⤷  Start Trial PRODUCT NAME: ACORAMIDIS Y/O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, ESPECIALMENTEHIDROCLORURO DE ACORAMIDIS; NATIONAL AUTHORISATION NUMBER: EU/1/24/1906; DATE OF AUTHORISATION: 20250210; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/24/1906; DATE OF FIRST AUTHORISATION IN EEA: 20250210
2934514 14/2025 Austria ⤷  Start Trial PRODUCT NAME: ACORAMIDIS UND/ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE ACORAMIDISHYDROCHLORID; REGISTRATION NO/DATE: EU/1/24/1906 (MITTEILUNG) 20250211
2934514 CA 2025 00013 Denmark ⤷  Start Trial PRODUCT NAME: ACORAMIDIS, AND/OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY ACORAMIDIS HYDROCHLORIDE; REG. NO/DATE: EU/1/24/1906 20250211
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.